258 related articles for article (PubMed ID: 33740735)
21. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
22. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
[TBL] [Abstract][Full Text] [Related]
23. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S; Iwata T; Kawada T; Okamoto Y; Sano Y; Kawago Y; Miyake S; Moriwake T; Kuinose A; Horikawa Y; Tsuboi K; Tsuboi I; Sakaeda K; Nakatsuka H; Takamoto A; Hirata T; Shirasaki Y; Yamasaki T; Morinaka H; Nagasaki N; Hara T; Ochi A; Okumura M; Watanabe T; Sekito T; Kawano K; Horii S; Yamanoi T; Nagao K; Yoshinaga K; Maruyama Y; Tominaga Y; Sadahira T; Nishimura S; Edamura K; Kobayashi T; Kusumi N; Kurose K; Yamamoto Y; Sugimoto M; Nakada T; Sasaki K; Takenaka T; Ebara S; Miyaji Y; Wada K; Kobayashi Y; Araki M
Urol Oncol; 2024 Mar; 42(3):70.e11-70.e18. PubMed ID: 38129282
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis.
Huang G; Xiong H; Li S; Zhu Y; Liu H
J Cancer Res Clin Oncol; 2024 Jan; 150(1):5. PubMed ID: 38170235
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
28. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
Tural D; Arslan C; Selcukbiricik F; Olmez OF; Akar E; Erman M; Ürün Y; Erdem D; Karadurmus N; Kilickap S
Clin Genitourin Cancer; 2023 Jun; 21(3):334-341. PubMed ID: 36641357
[TBL] [Abstract][Full Text] [Related]
29. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors.
Chawla NS; Sayegh N; Tripathi N; Govindarajan A; Zengin ZB; Phillip EJ; Dizman N; Meza L; Muddasani R; Chehrazi-Raffle A; Malhotra J; Hsu J; Agarwal N; Pal SK; Tripathi A
Clin Genitourin Cancer; 2023 Feb; 21(1):69-75. PubMed ID: 36509613
[TBL] [Abstract][Full Text] [Related]
30. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
31. Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study.
Raggi D; Giannatempo P; Marandino L; Pierantoni F; Maruzzo M; Lipari H; Banna GL; De Giorgi U; Casadei C; Naglieri E; Buti S; Bersanelli M; Stellato M; Santini D; Vignani F; Roviello G; Veccia A; Caffo O; Losanno T; Calabrò F; Mucciarini C; Pignata S; Necchi A; Maio MD;
Clin Genitourin Cancer; 2022 Apr; 20(2):155-164. PubMed ID: 35000876
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Su R; Chen Z; Hong D; Jiang S; Yuan Y; Cai X; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Huang J; Wang Z; Bao Y; Cai M; Guo J; Chen M; Wei Q; Huang J; Xue W
Cancer Med; 2023 May; 12(9):10587-10596. PubMed ID: 36952461
[TBL] [Abstract][Full Text] [Related]
33. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
[TBL] [Abstract][Full Text] [Related]
34. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
35. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
36. Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy.
Li H; An X; Huang R; Li L; Chu C; Yang W; Qin Z; Liu Z; Zhou F; Xue C; Shi Y
Front Mol Biosci; 2021; 8():621883. PubMed ID: 34458319
[No Abstract] [Full Text] [Related]
37. Outcomes of Patients with Advanced Urothelial Carcinoma after Anti-programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study.
Rezazadeh Kalebasty A; Benjamin DJ; Loriot Y; Papantoniou D; Siefker-Radtke AO; Necchi A; Naini V; Carcione JC; Santiago-Walker A; Triantos S; Burgess EF
Eur Urol Open Sci; 2023 Jan; 47():48-57. PubMed ID: 36601039
[TBL] [Abstract][Full Text] [Related]
38. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
[TBL] [Abstract][Full Text] [Related]
39. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
40. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
